hVIVO PLC
LSE:HVO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Blue Owl Capital Inc
NYSE:OWL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (9.5), the stock would be worth GBX-4.65 (160% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -15.8 | GBX7.75 |
0%
|
| 3-Year Average | 9.5 | GBX-4.65 |
-160%
|
| 5-Year Average | 9.9 | GBX-4.82 |
-162%
|
| Industry Average | 0 | GBX-0.01 |
-100%
|
| Country Average | 0 | GBX-0.01 |
-100%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
GBX65.3m
|
/ |
Jan 2026
£-3.2m
|
= |
|
|
GBX65.3m
|
/ |
Dec 2026
£-3.6m
|
= |
|
|
GBX65.3m
|
/ |
Dec 2027
£-741.6k
|
= |
|
|
GBX65.3m
|
/ |
Dec 2028
£7.1m
|
= |
|
|
GBX65.3m
|
/ |
Dec 2029
£11.9m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
hVIVO PLC
LSE:HVO
|
53.2m GBP | -15.8 | -8.9 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 2 361.7 | 4 280.5 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
176.7B USD | 24.7 | 26.4 | |
| US |
|
Danaher Corp
NYSE:DHR
|
125.4B USD | 25.9 | 34 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 39.4 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
298.9B CNY | 16.3 | 15.6 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
34.3B CHF | 25.4 | -118.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 22 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.4B USD | 38.4 | 47.3 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.5B USD | 17.2 | 20.3 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.1B USD | 24.7 | 30 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0.1 |
| Max | 1 015 |
Other Multiples
hVIVO PLC
Glance View
hVIVO PLC provides pharmaceutical development services. The firm is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The company provides end-to-end early clinical development services to its client base, which includes global biopharma companies. The company offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The company offers additional clinical field trial services, such as patient recruitment and clinical trial site services. The company runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.
